Roche’s Tecentriq secures FDA approval for small cell lung cancer treatment

Roche’s subsidiary, Genentech, has announced a significant breakthrough with the US Food and Drug Administration (FDA) approval of Tecentriq (atezolizumab). This new approval marks a pivotal development in the fight against extensive stage small cell lung cancer (ES-SCLC), as the monoclonal antibody will now be used in combination with chemotherapy as a first-line treatment for adult patients.

The chemotherapy regimen to be combined with Tecentriq consists of carboplatin and etoposide, two commonly used agents for small cell lung cancer. This approval is expected to enhance treatment options for a disease that has long been difficult to treat, especially in its advanced stages.

Tecentriq: A step forward in cancer immunotherapy

Tecentriq works by targeting the PD-L1 protein, which is found on both tumor cells and immune cells within the tumor microenvironment. By binding to PD-L1, Tecentriq blocks its interaction with the PD-1 and B7.1 receptors, potentially allowing the body’s immune system, specifically T cells, to be reactivated. This can result in more effective immune responses against the cancerous cells, improving the body’s ability to fight off the disease.

The latest FDA approval follows positive results from the phase 3 IMpower133 trial. The study demonstrated that Tecentriq, when used alongside chemotherapy, significantly improved the survival of patients compared to chemotherapy alone. In the trial, which enrolled 403 patients, those treated with the combination therapy showed a marked decrease in the risk of disease progression or death (progression-free survival, PFS).

Dr. Sandra Horning, Chief Medical Officer and Head of Global Product Development at Roche, expressed her excitement over the approval, emphasizing the impact it could have on the treatment of ES-SCLC. She noted that Tecentriq is the first cancer immunotherapy to be approved for the initial treatment of this particularly challenging form of cancer. Dr. Horning highlighted that the approval offers patients a potential new standard of care, one that has been shown to improve survival in clinical trials compared to traditional chemotherapy options.

Previous FDA approvals for Tecentriq

This new approval adds to Tecentriq’s growing list of FDA approvals. The immunotherapy was previously approved for use in combination with Avastin (bevacizumab) and chemotherapy (paclitaxel and carboplatin) as a first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC) in patients without EGFR or ALK genomic tumor aberrations. Additionally, Tecentriq is also approved for treating metastatic NSCLC in adult patients whose disease has progressed following treatment with platinum-containing chemotherapy.

The approval of Tecentriq for ES-SCLC reflects ongoing advancements in the use of immunotherapies to treat cancer, providing hope for patients battling difficult-to-treat cancers. With continued clinical validation, this therapy has the potential to change the standard of care for those suffering from small cell lung cancer, a condition with limited treatment options historically.